The aromatase inhibitors (AIs) anastrozole, letrozole, and exemestane are often prescribed as endocrine therapy for patients with estrogen receptor–positive breast cancer. AIs are associated with musculoskeletal side effects such as bone loss, arthralgias, myalgias, and tenosynovitis. Notably, exemestane is a steroidal AI and both anastrozole and letrozole are non-steroidal AIs.
Carlos H Barcenas
The University of Texas MD Anderson Cancer Center, Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Unit 1345, Houston TX, 77030, USA
View Profile
Huifang Lu
The University of Texas MD Anderson Cancer Center, Department of General Internal Medicine, Section of Rheumatology and Clinical Immunology, The University of Texas MD Anderson Cancer Center, 1400 Pressler St., Unit 1465 Houston, TX 77030, USA
View Profile